[1-(6-Methoxy-2-methylsulfanyl-pyrimidin-4-yl)-piperidin-3-yl]-methanol, 95.0%, 100mg

6-Bromo-N-methylnicotinamide, 95.0%, 500mg

N-[(9H-Fluoren-9-ylmethoxy)carbonyl]-N-methyl-L-isoleucine>98.0%(HPLC)(T)5g

2-Allyl-6-(methylthio)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one, 95.0%, 25g

(S)-2-(3-PYRROLIDINYL)-2-PROPANOL HCL, 95.0%, 250mg

(S)-4-Isopropyl-2-(6-methylpyridin-2-yl)-4,5-dihydrooxazole, 97%, 100mg

Methyl 3-methyl-1-phenyl-1H-pyrazole-5-carboxylate, 97%, 250mg

4-Hydroxy-2,2-dimethylcyclohexanone, 95.0%, 250mg

methyl6-methanesulfonylpyridine-3-carboxylate, 98%, 10g

Tert-butyl 4-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)piperidine-1-carboxylate, 98%, 250mg

Solution d'hypochlorite de sodium, 5-10% Cl, techn., 2,5 l, emballage plastique.

4-(3,5-dibromo-1H-1,2,4-triazol-1-yl)butanenitrile, 95.0%, 2g

3-Iodo-2-methoxybenzoic acid, 97%, 5g